Loading...
Loading...
ENVB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 114.4K |
| Gross Profit | -114.4K |
| Operating Expense | 5,755.0K |
| Operating I/L | -5,755.0K |
| Other Income/Expense | -601.0K |
| Interest Income | 0.9K |
| Pretax | -6,356.1K |
| Income Tax Expense | 607.8K |
| Net Income/Loss | -6,362.8K |
Enveric Biosciences, Inc. is a pharmaceutical company specializing in the development of cannabinoid medicines for cancer care. The company's product pipeline includes EV104 for osteoarthritis, EVM-101 and EVM-201 for cancer-related distress, EVM-301 for mental health indications, EV102, a cannabinoid cream for topical skin application, and EV101, a cannabinoid and chemotherapy combination therapy.
